Letters to the Editor

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm

Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Jacksonville FL
Division of Hematology, Mayo Clinic, Jacksonville FL
Division of Hematology, Mayo Clinic, Scottsdale, AZ
Division of Hematopathology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Haematologica Early view Dec 15, 2022 https://doi.org/10.3324/haematol.2022.282019